Synact ready for phase II with arthritis candidate: "An important milestone for the company"

After finishing phase I trials, Danish biotech company Synact has applied for the authorities' permission to initiate a phase II study with the company's lead candidate against rheumatoid arthritis. According to the CEO, the company has various financing opportunities.